Dare Bioscience (DARE) Receivables (2013 - 2022)

Dare Bioscience's (DARE) quarterly Receivables came in at $12.1 million in Q2 2022, up 1127.18% on a QoQ basis from $989070.0 in Q4 2021.

Dare Bioscience (DARE) Receivables (2013 - 2022) Analysis & Trends

Dare Bioscience (DARE) has 7 years of Receivables data on file, last reported at $12.1 million in Q2 2022.

Quarterly Receivables changed N/A year-over-year to $12.1 million in Q2 2022, while the trailing twelve-month figure through Jun 2022 was $12.1 million (changed N/A YoY) and the FY2021 annual result came in at $1.1 million, changed N/A from the prior year.
Receivables improved to $12.1 million in Q2 2022, from $989070.0 in the prior quarter.
In the past five years, Receivables ranged from a high of $12.1 million in Q2 2022 to a low of $989070.0 in Q4 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Vertex Pharmaceuticals	139.81 Bn	131.96 Bn	2.84 Bn	2.13 Bn
2	Regeneron Pharmaceuticals	86.56 Bn	78.56 Bn	3.93 Bn	6.57 Bn
3	Argenx Se	65.72 Bn	60.53 Bn	1.37 Bn	1.93 Bn
4	Moderna	58.75 Bn	53.61 Bn	52.00 Mn	160.00 Mn
5	BeOne Medicines	42.16 Bn	37.06 Bn	1.53 Bn	1.06 Bn
6	Alnylam Pharmaceuticals	31.76 Bn	28.45 Bn	992.69 Mn	912.74 Mn
7	BioNTech SE	28.59 Bn	10.19 Bn	668.28 Mn	1.09 Bn
8	Insmed	27.63 Bn	26.47 Bn	358.27 Mn	215.33 Mn
9	Royalty Pharma	27.24 Bn	26.40 Bn	-	-
10	Dare Bioscience	12.36 Mn	-256,055.23	-132,343.00	-

Download Data